Bristol Says It’s Ready For PD-1 Competition In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Opdivo sales got out of the gate slowly, but Bristol sees encouraging trends – and has a validated diagnostic for the PD-L1 therapy at the ready, if needed.